Purdue Sues To Block Abuse-Proof OxyContin Generics

Law360, New York (February 4, 2013, 7:23 PM EST) -- Purdue Pharma LP and Grunenthal GmbH on Friday sued two rivals in New York federal court, alleging their planned generic versions of painkiller OxyContin infringed two patents covering a so-called abuse-proof version of the drug.

According to the suits, abbreviated new drug applications by two units of Watson Pharmaceuticals Inc. — now a part of Actavis Inc. — and Impax Laboratories Inc. for generic oxycodone hydrochloride extended-release tablets, covering seven various dosage strengths between 10 and 80 milligrams, had infringed at least one of two patents...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.